Markman and Monk Provide Perspective on the Utility of PARP Inhibitors in Ovarian Cancer
In our exclusive interview, Bradley J. Monk, MD, FACS, FACOG, and Maurie Markman, MD, discuss the rationale behind maintenance therapy, pivotal PARP inhibitor trials in the frontline setting, and the importance of shared-decision making.
Welcome to a very special edition of OncLive® On Air! I’m your host today, Caroline Seymour.
OncLive® On Air is a podcast from OncLive, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, sponsored by GlaxoSmithKline, we passed the mic to Bradley J. Monk, MD, FACS, FACOG, US oncology medical director of Gynecologic Oncology Research and professor at the University of Arizona College of Medicine, and Maurie Markman, MD, physician and president of medicine and science at Cancer Treatment Centers of America, and the editor-in-chief of our flagship publication, OncologyLive, to discuss the evolution of treatment in advanced ovarian cancer and provide perspective on the current utility of PARP inhibitors as frontline maintenance therapy.
In our exclusive interview, Dr. Monk and Dr. Markman discussed the rationale behind maintenance therapy, pivotal PARP inhibitor trials in the frontline setting, and the importance of shared-decision making.
Sponsored by:
